Treatments for Parkinson’s disease: good news!
Last month, the National Institute of Excellence in Health and Social Services (INESSS) recommended that the Minister of Health and Social Services place Movapo on the list of medications for the treatment of patients with Parkinson’s disease at an advanced stage.
Parkinson Québec is proud to have been able to contribute to the reflection surrounding this decision by submitting, among other things, a favorable recommendation for this drug to INESSS. Thanks also to the caregivers and Parkinson’s patients we asked for their feedback on this drug and the benefits it could provide.
Movapo (or apomorphine) is indicated for the acute and intermittent treatment of dyskinesias and “off” periods. Among the inconveniences associated with the “off” phase, there may be abdominal pain and painful cramps especially in the calves or foot. Also, non-motor problems can occur, such as incontinence, concentration problems or fatigue. Anxiety is also frequently associated with this phase.
For more information on this decision, please consult directly the recommendation issued by INESSS, by clicking here.